Tarsus to Participate in Upcoming Investor Conferences

Tarsus Pharmaceuticals (NASDAQ: TARS) management plans to attend three upcoming investor conferences, including fireside chats at Guggenheim and Piper Sandler.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) management plans to attend three upcoming investor conferences, including fireside chats at Guggenheim and Piper Sandler.

The Guggenheim chat is November 10 at 12:30 p.m. PT; Jefferies attendance is November 18–19; and the Piper Sandler chat is December 1 at 11:30 a.m. PT. Live webcasts and additional information will be available on the company website, with replays available within 48 hours for a limited time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/05/2026 - 04:30 PM EST

IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:

Guggenheim 3^rd Annual Healthcare Conference on Tuesday, November 10^th, where management plans to participate in a fireside chat at 12:30 p.m. PT / 3:30 p.m. ET.
2026 Jefferies Global Healthcare Conference on Wednesday, November 18^th and Thursday, November 19^th.
Piper Sandler 38^th Annual Healthcare Conference on Tuesday, December 1^st, where management plans to participate in a fireside chat at 11:30 a.m. PT / 2:30 p.m. ET.

Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea, TP-05 as an oral tablet for the potential prevention of Lyme disease, IRX-101 for potential use as an ocular antiseptic and gildeuretinol for the potential treatment of Stargardt disease.

Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com